. Author manuscript; available in PMC: 2016 Apr 12.

Published in final edited form as: J Med Chem. 2016 Jan 29;59(3):1207–1216. doi: 10.1021/acs.jmedchem.5b01910

Table 4.

Exploring 1,3,4-Oxadiazole, 1,3,4-Thiadiazole, and Thiazole^b

Compound ID	%S31N inhibition^*	%WT inhibition^*	% plaque formation at 1 µM (A/WSN/33)^**	CC₅₀ (µM)
26a	52/N.T.	16	N.T.	N.T.
26b	83/N.T.	21	39±2	>200
26c	61/N.T.	18	N.T.	N.T.
26d	58/N.T.	3	N.T.	N.T.
26e	75/N.T.	13	N.T.	113
26f^a	38/N.T.	5	N.T.	N.T.
26g^a	28/N.T.	22	N.T.	N.T.
26h	37/N.T.	7	N.T.	N.T.
26i	24/N.T.	0	N.T.	N.T.
26j^a	36/N.T.	57	N.T.	N.T.

Percent inhibition in TEVC assays was previously reported.

^b*

Values represent the mean of three independent measurements. We typically see no more than 5% variation in the percent inhibition on a given day, or 10% error for measurements made on different days with different batches of oocytes. The data are presented as percent inhibition at 100 µM/percent inhibition at 30 µM. N.T. = not tested.

^**

Plaque reduction assays were performed against the M2-S31N containing A/WSN/33 virus in duplicates. The percent of plaque formation is defined as the ratio of plaque numbers in the presence of compounds divided by the plaque numbers in the absence of compounds